3月27日 - ** Soleno Therapeutics SLNO.O股价盘前上涨33.98%至65.61美元
** 周三晚些时候，美国食品和药物管理局（FDA）批准了 (link) co 公司治疗一种罕见遗传性疾病的药物，使其成为首个可用于治疗有强烈和持续饥饿感的患者的药物。
** 该药名为 Vykat XR，可治疗食欲亢进症，这是普拉德-威利综合症的标志性症状，而普拉德-威利综合症是一种由一个或多个基因错误引起的遗传性疾病。
** 这种药物的年平均成本为 46.62 万美元，将根据患者的体重配药，并将于 4 月起上市。
** 截至上次收盘，股价累计上涨约 9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.